Top Story

Bevacizumab plus chemotherapy improves OS in recurrent ovarian cancer

March 31, 2015

The addition of bevacizumab to a standard chemotherapy regimen conferred a median 5-month survival improvement among women with ovarian cancer, according to results of a phase 3 study presented at the Society of Gynecologic Oncology’s Annual Meeting on Women’s Cancer.

Robert L. Coleman, MD, FACOG, FACS, the Ann Rife Cox chair in gynecology, vice chair of clinical research and professor in the department of gynecologic oncology and reproductive medicine at The University of Texas MD Anderson Cancer Center, and colleagues sought to evaluate the addition of bevacizumab (Avastin, Genentech) to standard chemotherapy followed by bevacizumab maintenance in women with platinum-sensitive, recurrent ovarian cancer. Researchers also sought to evaluate the role of secondary cytoreduction before chemotherapy initiation in this population; however, enrollment for this phase is ongoing.

David Weinberg In the Journals

AGA guideline recommends change in diagnosis, management of asymptomatic pancreatic cysts

March 31, 2015
The American Gastroenterological Association has released a new guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts, which recommends…
FDA News

FDA strengthens warning, changes prescribing instructions for Feraheme

March 31, 2015
The FDA approved the addition of a boxed warning and updated the prescribing instructions for the anemia drug ferumoxytol, according to a press release from the…
FDA News

FDA approves Jadenu for chronic iron overload

March 31, 2015
The FDA announced the approval of Jadenu tablets for the treatment of certain patients with chronic iron overload, according to a press release from the drug’s…
Darius N. Lakdawalla, PhD In the Journals

Value of PFS as surrogate in NSCLC varies considerably

March 31, 2015
The value of providing access to new treatments for non–small cell lung cancer based on improvements in PFS varied according to incremental treatment cost, the…
More News Headlines »
Low Risk AAMDS

Treatment Decision-Making through the Spectrum of MDS:
Case 1 Low Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain MDS…
More »
Meeting News Coverage Video
thumbnail for video 4126759064001

Solid organ transplant recipients at higher risk for skin cancer

March 22, 2015
SAN FRANCISCO – In this video, Sarah Tuttleton Arron, MD, PhD, FAAD, discusses her research on mortality from…
More »
Activity cover

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates

This activity is supported by an educational grant from Merck & Co., Inc.

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »